I have just read all comments below posted on the FDA website. Lassman Law firm on top of the game against approval of the Rynocil. They have already submitted TWO comments against the approval. I don't know they have constructive points but they have well presented
https://beta.regulations.gov/document/FDA-2020-N-1539-0022/comment
From MSB side will need something constructive, professional, and well-documented comment on FDA website before the 13th. I would like to know how many times Lassman Law firm had commented against the approval and FDA still approved that product.
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-248
-
- There are more pages in this discussion • 607 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |